Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Active Not Recruiting2
Withdrawn1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04721132Phase 2Active Not Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

NCT05194293Phase 2Active Not RecruitingPrimary

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

NCT05157451Phase 2Withdrawn

Y-90 Versus SBRT for Inoperable HCC

Showing all 3 trials

Research Network

Activity Timeline